National data shows COVID-19 levels are moderate. In most of the U.S., levels of other respiratory viruses are low, although RSV is ticking up in some southeastern states.

In August, the FDA approved the first vaccine for pregnant people that protects newborns against infections from respiratory syncytial virus, one of the leading causes of hospitalizations among infants and young children. 

The Food and Drug Administration has approved the first vaccine for expectant mothers to shield their babies from RSV.

The monoclonal antibody drug prevents the lung infection that puts 58,000 to 80,000 young children in the hospital each year.

At least 58,000 childern younger than 5 years old are hospitalized each year with RSV infections. A Pfizer vaccine given to pregnant people could help protect their infants from severe RSV illness.